The short answer
Alpha-lipoic acid supplements have been linked to a rare cause of low blood sugar. Review DL-alpha-lipoic acid with the liraglutide prescriber; the risk of this exact combination has not been measured.
What this answer covers
DL-alpha-lipoic acid is a racemic supplement. Original case reports do not consistently identify the stereoisomer; food-bound ALA and pure R-ALA are distinguished.
- Supplement or preparation
- DL-alpha-Lipoic acid
- Medication ingredient
- liraglutide
What the original cases show
Published cases describe severe or recurring low blood sugar with insulin autoantibodies after ALA supplementation. One patient had further episodes after taking ALA again. Neither report established liraglutide co-use.
Why the form matters
The safety assessment distinguishes supplemental racemic and R-ALA from ALA naturally bound in food. The reports do not define a reliably safe supplemental dose or prove that all forms have equal risk. Check that the bottle actually contains DL-alpha-lipoic acid.
Review unexplained low readings
Repeated unexpected low glucose warrants prompt medical review, including the supplement history. Insulin autoimmune syndrome is a different mechanism from ordinary glucose-lowering treatment; the clinician may investigate it when appropriate.
Keep the prescribed medicine plan
Confirm whether the prescription is VICTOZA for diabetes or SAXENDA for weight management. Their daily injection doses and indications differ. Report persistent vomiting, diarrhea or reduced eating, and do not alter the injection dose to compensate for a supplement.
Watch for low blood sugar
Follow your existing glucose-monitoring and low-blood-sugar treatment plan. New sweating, shakiness, hunger or confusion warrants a glucose check when possible. Severe confusion, a seizure or inability to swallow safely needs emergency help.
Evidence and practical considerations
Side effects & toxicity
Conditional glucose safety concern based on ALA insulin autoimmune syndrome reports and exact liraglutide treatment context, not proof of additive pair hypoglycemia.
- Exact scope
- DL-alpha-lipoic acid is a racemic supplement. Original case reports do not consistently identify the stereoisomer; food-bound ALA and pure R-ALA are distinguished. with Exact liraglutide subcutaneous daily injection, diabetes and weight-management products distinguished. Exact RxNorm IN475968 liraglutide; subcutaneous daily injection, diabetes and weight-management products distinguished. Combination medicines are not assumed equivalent. VICTOZA and SAXENDA differ in indications and doses; neither is weekly dulaglutide.
- Medication form and route
- subcutaneous
- Timing or duration
- Source-specific single-dose, repeated-dose and observational exposures distinguished.
What remains uncertain
- No exact DL-ALA/liraglutide human trial identified. Case preparation identity is limited; R-ALA animal combination studies cannot establish a human DL-ALA effect.
Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline glucose and nutrient status.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: People prescribed liraglutide.
Glucose-dependent GLP1 action, dose/indication-specific hypoglycemia, gastrointestinal effects and delayed gastric emptying.
How this applies: Exact RxNorm IN475968 liraglutide; subcutaneous daily injection, diabetes and weight-management products distinguished. Combination medicines are not assumed equivalent. VICTOZA and SAXENDA differ in indications and doses; neither is weekly dulaglutide.
No universal supplement dose, interval, event rate or untested formulation equivalence.
Source 2: original case report
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: A 55-year-old man without prior insulin administration.
Insulin autoantibodies and a susceptible HLA genotype were found after hypoglycemia with loss of consciousness.
How this applies: Only the named drug, preparation, route and measured endpoints apply.
Case report does not identify DL versus R preparation or liraglutide exposure. Full text contains inconsistent dose figures, so no dose threshold is inferred.
Source 3: original case report
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: A 67-year-old woman with type 2 diabetes and neuropathy.
Hypoglycemic episodes recurred after re-exposure; insulin antibodies and HLA susceptibility were documented.
How this applies: Only the named drug, preparation, route and measured endpoints apply.
No liraglutide co-use or stereoisomer confirmation in inspected abstract; no incidence estimate.
Source 4: official safety assessment
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: Published alpha-lipoic acid case reports reviewed by EFSA.
EFSA judged a risk of insulin autoimmune syndrome in susceptible individuals; a reliably safe supplemental dose could not be established.
How this applies: Only the named drug, preparation, route and measured endpoints apply.
Official assessment, not an exact DL-alpha-lipoic acid/liraglutide trial. Individual case formulation identity remains limited.
Source 5: current product label
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: People prescribed SAXENDA for labeled weight management.
Hypoglycemia precautions depend on diabetes, age and concomitant insulin or secretagogues; gastrointestinal effects and delayed gastric emptying are described.
How this applies: Exact liraglutide weight-management formulation.
Not a vitamin absorption study or a weekly injection; VICTOZA has a different indication and dose.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Current exact available claims adjudicated using original captures and explicit identity and comparator limits. |
Article revision: 774a5b5dacc223bc
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.